Before-surgery immunotherapy for stage III melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests immunotherapy given before surgery to help shrink or control stage III melanoma that has spread to nearby areas (lymph nodes/region). If it works, it may improve outcomes after the melanoma is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, and you have skin melanoma confirmed by pathology
- You can do usual activities (performance status 0 or 1) and your blood, liver, kidney, and clotting labs are adequate
- Your melanoma has been fully removed, and you have stage III disease that can be surgically treated (stage III resectable)
- You must have at least one measurable spot and an injectable lymph node that the team can treat directly
- You have not had treatment with pembrolizumab (or similar PD-1/PD-L1/PD-L2 drugs) or other oncolytic virus treatments like T-VEC
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial is for people with stage III melanoma that can be surgically removed. It compares one immunotherapy drug to a combination of two, to see which works better before surgery.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. The drugs are given to boost your immune system to attack the cancer before it's removed.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.